Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy-Reference-Cited by-同舟云学术

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy

Published:2009-10-02 Issue:1 Volume:19 Page:75-81
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidem. Drug Safe.

Author:

Becker Matthijs L.,Visser Loes E.,van Schaik Ron H. N.,Hofman Albert,Uitterlinden André G.,Ch. Stricker Bruno H.

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.1866/fullpdf

Reference29 articles.

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Scandinavian Simvastatin Survival Study Group;Lancet,1994

2. The safety of statins in clinical practice;Armitage;Lancet,2007

3. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors;Jacobson;Am J Cardiol,2004

4. Flockhart DA Drug Interactions: cytochrome P450 Drug Interaction Table 2007 http://medicine.iupui.edu/flockhart/table.htm

5. In vitro metabolism of simvastatin in humans identification of metabolizing enzymes and effect of the drug on hepatic P450s;Prueksaritanont;Drug Metab Dispos,1997

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When the same treatment has different response: The role of pharmacogenomics in statin therapy;Biomedicine & Pharmacotherapy;2024-01

2. Predicting novel targets with Bayesian machine learning by integrating multiple biological signatures;Chemical Science;2024

3. Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study;Scientific Reports;2023-10-19

4. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?;European Journal of Medical Research;2023-09-27

5. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database;Drug Metabolism and Pharmacokinetics;2023-04